IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine
Background: Interleukin (IL)17A is a member of the IL17 cytokine family, which is released by both immune and non-immune cells such as tumor and stromal cells into the tumor microenvironment. IL17 receptors are also widely expressed in different type of cells. Among all the members, IL17A is the mos...
Main Authors: | Cecilia Roux, Gianluca Mucciolo, Joanna Kopecka, Francesco Novelli, Chiara Riganti, Paola Cappello |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/10/3/422 |
Similar Items
-
The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer
by: Jiahui Li, et al.
Published: (2020-03-01) -
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type
by: Joseph Fabre, et al.
Published: (2016-08-01) -
IL-17A Induces Pro-Inflammatory Cytokines Production in Macrophages via MAPKinases, NF-κB and AP-1
by: Jian Chen, et al.
Published: (2013-11-01) -
Interleukin-17A (IL-17A): A silent amplifier of COVID-19
by: Francesco Maione, et al.
Published: (2021-10-01) -
IL-17A promotes intracellular growth of Mycobacterium by inhibiting apoptosis of infected macrophages
by: Andrea eCruz, et al.
Published: (2015-09-01)